Context Therapeutics reports Q2 results
Source: SeekingAlpha
2025-08-07 11:33:41 ET
More on Context Therapeutics
- Context Therapeutics: Undervalued Cancer Fighter
- Seeking Alpha’s Quant Rating on Context Therapeutics
- Historical earnings data for Context Therapeutics
- Financial information for Context Therapeutics
Read the full article on Seeking Alpha
For further details see:
Context Therapeutics reports Q2 results
Context Therapeutics Inc.
NASDAQ: CNTX
CNTX Trading
2.71% G/L:
$3.035 Last:
491,417 Volume:
$2.92 Open:
CNTX Latest News
December 16, 2025 12:18:00 pm
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
November 07, 2025 07:30:00 am
Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting
November 05, 2025 04:15:57 pm
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results
CNTX Stock Data
$216,834,858
38,589,254
2.16%
12
N/A
Biotechnology & Life Sciences
Healthcare
US
Philadelphia
